^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Precursor-M+/QIAsure Methylation Test

Company:
Self-screen
Type:
CE Marked
Related tests:
Evidence

News

2ms
Trial completion
|
CINtec® PLUS Cytology • Precursor-M+/QIAsure Methylation Test
3ms
HIPPOPROJECT: HPV Testing In Polish POpulation-based Cervical Cancer Screening Program. (clinicaltrials.gov)
P=N/A; N=33000; Active, not recruiting; Sponsor:Maria Sklodowska-Curie National Research Institute of Oncology
Trial completion date
|
CINtec® PLUS Cytology • Precursor-M+/QIAsure Methylation Test
3ms
Comparing the Costs and Diagnostic Outcomes of Replacing Cytology with the QIAsure DNA Methylation Test as a Triage within HPV Primary Cervical Cancer Screening in The Netherlands. (PubMed)
Irrespective of relative performance, the cost per complete screen was lower and fewer people were lost to follow-up when using DNA methylation testing. The results indicate that, within an HPV primary screening programme that incorporates self-sampling, using the QIAsure Methylation Test for triage reduces the cost per screen compared to LBC.
Journal • Epigenetic controller • Cytology
|
Precursor-M+/QIAsure Methylation Test
8ms
MANAGEMENT AND STRATIFICATION OF PATIENTS WITH AGC-FN PAP SMEAR (ESGO 2023)
In the HPV negative subgroup we recommend an close examination of the uterine cavity and pelvic organs in addition to colposcopy/biopsy. In our experience, irrespective of HPV status, a positive methylation test predicts precancer or malignancy.
Clinical
|
Precursor-M+/QIAsure Methylation Test
over1year
Fujirebio Europe Receives Distribution Rights to Market Self-screen’s PreCursor-M+ Methylation-specific Molecular Assay, a Powerful Solution to Identify Women at High Risk for Cervical Cancer (Self-screen Press Release)
"Fujirebio Europe and Self-screen B.V. today announce a commercial collaboration around the distribution of the PreCursor-M+ methylation-specific molecular IVD assay from Self-screen B.V. The test is intended for the qualitative detection of elevated methylation levels of cervical cancer biomarkers and may be used as a triage follow-up test of human papillomavirus (HPV) positive women and women with ASCUS/ LSIL cytology results. It complements Fujirebio's HPV-specific molecular test portfolio."
Licensing / partnership
|
Precursor-M+/QIAsure Methylation Test